Carcinogenesis of PIK3CA

Hereditary Cancer in Clinical Practice

Volumn 11, Issue 1, 2013, Pages

  German, Sidra ^a   Aslam, Hafiz Muhammad ^a,b   Saleem, Shafaq ^a   Raees, Aisha ^a   Anum, Tooba ^a   Alvi, Arsalan Ahmad ^a   Haseeb, Abdul ^a  

^a DOW UNIVERSITY OF HEALTH SCIENCES   (Pakistan)

^b not available   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; TEMSIROLIMUS;

ANAPLASTIC THYROID CANCER; BREAST CANCER; CANCER PATIENT; CARCINOGENESIS; CELL DEATH; CELL DIFFERENTIATION; CELL GROWTH; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; CHONDROMA; COLORECTAL CANCER; COWDEN SYNDROME; ENDOMETRIUM CANCER; ENZYME ACTIVE SITE; ENZYME ACTIVITY; FAMILIAL CANCER; FAMILIAL COLON POLYPOSIS; GLIOBLASTOMA; HUMAN; INVASIVE CARCINOMA; KIDNEY CARCINOMA; LETTER; MOLECULARLY TARGETED THERAPY; MUTATION RATE; ONCOGENE; OVARY CANCER; PROSTATE CARCINOMA; SIGNAL TRANSDUCTION; SOMATIC MUTATION; SQUAMOUS CELL CARCINOMA; THYROID ADENOMA; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; UTERINE CERVIX CANCER;

EID: 84878894325     PISSN: 17312302     EISSN: 18974287     Source Type: Journal    
DOI: 10.1186/1897-4287-11-5     Document Type: Letter

References (23)

1. Whitman M, Kaplan DR, Schaffhausen B, Cantley L, Roberts TM. Association of phosphatidylinositol kinase activity with polyoma middle-T competent for transformation. Nature 1985, 315(6016):239-242.
2. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol 2010, 28(6):1075-1083.
3. Kelley LC, Shahab S, Weed SA. Actin cytoskeletal mediators of motility and invasion amplified and overexpressed in head and neck cancer. Clin Exp Metastasis 2008, 25(4):289-304.
4. Leevers SJ, Vanhaesebroeck B, Waterfield MD. Signalling through phosphoinositide 3-kinases: the lipids take centre stage. Curr Opin Cell Biol 1999, 11(2):219-225.
5. PIK3CA phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha Homo sapiens (human) http://www.ncbi.nlm.nih.gov/gene/5290.
6. Whyte DB, Holbeck SL. Correlation of PIK3Ca mutations with gene expression and drug sensitivity in NCI-60 cell lines. Biochem Biophys Res Commun 2006, 340(2):469-475.
7. Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, Naing A, Falchook GS, Moroney JW, Piha-Paul SA. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther 2011, 10(3):558-565.
8. Kurek KC, Luks VL, Ayturk UM, Alomari AI, Fishman SJ, Spencer SA, Mulliken JB, Bowen ME, Yamamoto GL, Kozakewich HP. Somatic Mosaic Activating Mutations in PIK3CA Cause CLOVES Syndrome. Am J Hum Genet 2012, 90(6):1108-1115.
9. Broderick DK, Di C, Parrett TJ, Samuels YR, Cummins JM, McLendon RE, Fults DW, Velculescu VE, Bigner DD, Yan H. Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res 2004, 64(15):5048-5050.
10. García-Rostán G, Costa AM, Pereira-Castro I, Salvatore G, Hernandez R, Hermsem MJ, Herrero A, Fusco A, Cameselle-Teijeiro J, Santoro M. Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res 2005, 65(22):10199-10207.
11. Wu G, Mambo E, Guo Z, Hu S, Huang X, Gollin SM, Trink B, Ladenson PW, Sidransky D, Xing M. Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors. J Clin Endocrinol Metab 2005, 90(8):4688-4693.
12. Abubaker J, Jehan Z, Bavi P, Sultana M, Al-Harbi S, Ibrahim M, Al-Nuaim A, Ahmed M, Amin T, Al-Fehaily M. Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population. J Clin Endocrinol Metab 2008, 93(2):611-618.
13. Gallia GL, Rand V, Siu I-M, Eberhart CG, James CD, Marie SK, Oba-Shinjo SM, Carlotti CG, Caballero OL, Simpson AJ. PIK3CA gene mutations in pediatric and adult glioblastoma multiforme. Mol Cancer Res 2006, 4(10):709-714.
14. Bonvin E, Falletta P, Shaw H, Delmas V, Goding CR. A Phosphatidylinositol 3-Kinase-Pax3 Axis Regulates Brn-2 Expression in Melanoma. Mol Cell Biol 2012, 32(22):4674-4683.
15. Allgayer H, Rehder H, Fulda S. Hereditary Tumors 2009, Wiley-Blackwell.
16. Orloff MS, He X, Peterson C, Chen F, Chen J-L, Mester JL, Eng C. Germ line PIK3CA and AKT1 Mutations in Cowden and Cowden-like Syndromes. Am J Hum Genet 2012, 92(1):76-80.
17. Miyaki M, Iijima T, Yamaguchi T, Takahashi K, Matsumoto H, Yasutome M, Funata N, Mori T. Mutations of the PIK3CA gene in hereditary colorectal cancers. Int J Cancer 2007, 121(7):1627-1630.
18. Ekstrand AI, Jonsson M, Lindblom A, Borg A, Nilbert M. Frequent alterations of the PI3K/AKT/mTOR pathways in hereditary nonpolyposis colorectal cancer. Fam Cancer 2010, 9(2):125-129.
19. Yamamoto S, Tsuda H, Takano M, Iwaya K, Tamai S, Matsubara O. PIK3CA mutation is an early event in the development of endometriosis-associated ovarian clear cell adenocarcinoma. J Pathol 2011, 225(2):189-194.
20. Rinner B, Weinhaeusel A, Lohberger B, Froehlich EV, Pulverer W, Fischer C, Meditz K, Scheipl S, Trajanoski S, Guelly C. Chordoma Characterization of Significant Changes of the DNA Methylation Pattern. PLoS One 2013, 8(3):e56609.
21. Garcia-Dios DA, Lambrechts D, Coenegrachts L, Vandenput I, Capoen A, Webb PM, Ferguson K, Akslen LA, Claes B, Vergote I, et al. High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma. Gynecol Oncol 2013, 128(2):327-334.
22. Sun X, Huang J, Homma T, Kita D, Klocker H, Schafer G, Boyle P, Ohgaki H. Genetic alterations in the PI3K pathway in prostate cancer. Anticancer Res 2009, 29(5):1739-1743.
23. Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, Imamura Y, Qian ZR, Baba Y, Shima K. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 2012, 367(17):1596-1606.